Moreover, c-MYC amplified chemotherapy-resistant ovarian cancer cells were demonstrated to be highly sensitive to combinational JQ1 and GS-626510, a bromodomain and extra-terminal motif inhibitor [75]. This evidence concerns the gene MYC and ovarian carcinoma.